AbbVie Makes $63B Bid for Botox Maker Allergan - NBC4 Washington
National & International News
The day’s top national and international news

AbbVie Makes $63B Bid for Botox Maker Allergan

Regulators and Allergan shareholders still need to approve the deal



    How Weight Loss Surgery Helped a Patient Rediscover His Voice
    This March 20, 2002 file photo shows a vial of Botox, made by Allergan. (AP Photo/Damian Dovarganes)

    AbbVie is buying Botox maker Allergan in a cash-and-stock deal valued at about $63 billion.

    The maker of the blockbuster immune disorder treatment Humira said Tuesday that it will pay $120.30 in cash and a portion of AbbVie stock for each Allergan share. That amounts to $188.24 per share, or a 45% premium to Allergan's closing price Monday.

    Shares of Allergan Plc, based in Dublin, Ireland, jumped nearly 30% before the opening bell.

    AbbVie shareholders will own 83% of the specialty drug company combination after the deal's completion while Allergan shareholders will have a 17% stake.

    Golf Ball Kills 6-Year-Old

    [NATL] Golf Ball Kills 6-Year-Old

    Community members in Orem, Utah are in shock after a freak golfing accident killed a little girl. Investigators say 6-year-old Aria Hill was sitting in a golf cart next to a tee box when her father hit a ball that struck her in the back of the head.

    (Published Wednesday, July 17, 2019)

    Regulators and Allergan shareholders still have to approve the deal.

    Shares of AbbVie Inc., based in North Chicago, Illinois, sank 10%.